奥布替尼在分枝杆菌感染宿主巨噬细胞中的免疫调控作用

doi:10.19982/j.issn.1000-6621.20240240

摘要/Abstract

摘要：

目的: 探讨新型布鲁顿酪氨酸激酶(Bruton tyrosine kinase,BTK)抑制剂奥布替尼在结核分枝杆菌(Mycobacterium tuberculosis,MTB)感染宿主巨噬细胞中的免疫调控作用。方法: 通过人急性单核白血病细胞(human acute monocytic leukemia cells,THP-1)培养与分化,用耻垢分枝杆菌感染分化后的THP-1细胞,并以不同浓度的奥布替尼处理,比较其对巨噬细胞吞噬和清除耻垢分枝杆菌的能力。利用siRNA干扰技术敲低BTK蛋白表达,通过蛋白免疫印迹法验证敲除效果,并使用菌落形成单位(CFU)计数法检测奥布替尼对巨噬细胞胞内耻垢分枝杆菌的清除能力。结果: 奥布替尼能够明显抑制BTK的酪氨酸磷酸化而不改变BTK蛋白的表达量,同时奥布替尼处理后的巨噬细胞胞内耻垢分枝杆菌菌落计数从130.0(120.3~137.5)×10³个/ml下降至59.0(55.8~65.3)×10³个/ml,差异有统计学意义(U=0.000,P=0.014)。在敲低BTK蛋白表达后,巨噬细胞内耻垢分枝杆菌的载菌量由52.0(44.0~61.5)×10³个/ml降低至25.0(22.0~28.0)×10³个/ml,差异有统计学意义(U=9.000,P=0.002)。结论: BTK在巨噬细胞功能调节中起关键作用,奥布替尼作为新型BTK抑制剂,不仅能够抑制BTK酪氨酸磷酸化,还能明显增强巨噬细胞对耻垢分枝杆菌的清除能力,为其潜在抗结核应用提供了新的思路。

关键词: 分枝杆菌, 结核, 蛋白酪氨酸激酶类, 巨噬细胞, 奥布替尼

Abstract:

Objective: To investigate the immunomodulatory effect of a novel Bruton tyrosine kinase (BTK) inhibitor orelabrutinib, in host macrophages infected with Mycobacterium tuberculosis (MTB). Methods: Human acute monocytic leukemia (THP-1) cells were cultured and differentiated. The differentiated THP-1 cells were infected with Mycobacterium smegmatis (M.smeg) and then treated with different concentrations of orelabrutinib to compare the ability of macrophages to engulf and clear M.smeg. BTK protein expression was knocked down by using siRNA interference technology, and the knockdown effect was verified by Western blotting. The colony-forming unit (CFU) assay was used to measure the clearance ability of macrophages against M.smeg by treated with orelabrutinib. Results: Orelabrutinib significantly inhibited the tyrosine phosphorylation of BTK without changing the level of BTK protein expression. Additionally, the CFU count of M.smeg in macrophages treated with orelabrutinib decreased from 130.0 (120.3-137.5)×10³/ml to 59.0 (55.8-65.3)×10³/ml, with statistical significance (U=0.000, P=0.014). After knocking down BTK protein expression, the bacterial load of M.smeg in macrophages decreased from 52.0 (44.0-61.5)×10³/ml to 25.0 (22.0-28.0)×10³/ml, with statistical significance (U=9.000, P=0.002). Conclusion: BTK plays a crucial role in macrophage functional regulation. As a novel BTK inhibitor, orelabrutinib not only suppresses BTK tyrosine phosphorylation but also significantly enhances the clearance ability of macrophage against M.smeg, providing a new perspective for its potential anti-tuberculosis applications.

Key words: Mycobacterium tuberculosis, Protein-tyrosine kinases, Macrophages, Orelabrutinib

中图分类号:

R516
R378.91

王艺霖, 吴潇, 逄宇, 李姗姗. 奥布替尼在分枝杆菌感染宿主巨噬细胞中的免疫调控作用[J]. 中国防痨杂志, 2024, 46(9): 1063-1068. doi: 10.19982/j.issn.1000-6621.20240240

Wang Yilin, Wu Xiao, Pang Yu, Li Shanshan. Immunomodulatory effect of orelabrutinib in host macrophages infected with mycobacterium[J]. Chinese Journal of Antituberculosis, 2024, 46(9): 1063-1068. doi: 10.19982/j.issn.1000-6621.20240240

图/表 5

图1

图2

图3

图4

图5

参考文献 28

[1]	Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton’s tyrosine kinase in B cell malignancies. Nat Rev Cancer, 2014, 14(4): 219-232. doi:10.1038/nrc3702. pmid: 24658273
[2]	Rada M, Barlev N, Macip S. BTK: a two-faced effector in cancer and tumour suppression. Cell Death Dis, 2018, 9(11): 1064. doi:10.1038/s41419-018-1122-8.
[3]	Wen T, Wang J, Shi Y, et al. Inhibitors targeting Bruton’s tyrosine kinase in cancers: drug development advances. Leukemia, 2021, 35(2): 312-332. doi:10.1038/s41375-020-01072-6.
[4]	Hu Y, Wen Z, Liu S, et al. Ibrutinib suppresses intracellular Mycobacterium tuberculosis growth by inducing macrophage autophagy. J Infect, 2020, 80(6): e19-e26. doi:10.1016/j.jinf.2020.03.003.
[5]	Dhillon S. Orelabrutinib: First Approval. Drugs, 2021, 81(4): 503-507. doi:10.1007/s40265-021-01482-5. pmid: 33704654
[6]	Xu W, Song Y, Li Z, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood, 2019, 134(Supplement_1): 4319-4319. doi:10.1182/blood-2019-123331.
[7]	中国临床肿瘤学会(CSCO)淋巴瘤专家委员会. 奥布替尼治疗B细胞淋巴瘤中国专家推荐临床应用指导原则(2021年版). 白血病·淋巴瘤, 2021, 30(8): 455-460. doi:10.3760/cma.j.cn115356-20210723-00162.
[8]	Deng LJ, Zhou KS, Liu LH, et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study. Blood Adv, 2023, 7(16): 4349-4357. doi:10.1182/bloodadvances.2022009168. pmid: 37078706
[9]	Qiu J, Fu Y, Chen Z, et al. BTK Promotes Atherosclerosis by Regulating Oxidative Stress, Mitochondrial Injury, and ER Stress of Macrophages. Oxid Med Cell Longev, 2021, 2021: 9972413. doi:10.1155/2021/9972413.
[10]	Xu X, Xu J, Wu J, et al. Phosphorylation-Mediated IFN-gammaR2 Membrane Translocation Is Required to Activate Macrophage Innate Response. Cell, 2021, 184(5):1393-1394. doi:10.1016/j.cell.2020.02.037.
[11]	Yang Y, Li S, Wang Y, et al. Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. Signal Transduct Target Ther, 2022, 7(1):329. doi:10.1038/s41392-022-01168-8.
[12]	Jiao Q, Bi L, Ren Y, et al. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer, 2018, 17(1): 36. doi:10.1186/s12943-018-0801-5.
[13]	Korbee CJ, Heemskerk MT, Kocev D, et al. Combined chemical genetics and data-driven bioinformatics approach identifies receptor tyrosine kinase inhibitors as host-directed antimicrobials. Nat Commun, 2018, 9(1): 358. doi:10.1038/s41467-017-02777-6.
[14]	Sogi KM, Lien KA, Johnson JR, et al. The Tyrosine Kinase Inhibitor Gefitinib Restricts Mycobacterium tuberculosis Growth through Increased Lysosomal Biogenesis and Modulation of Cytokine Signaling. ACS Infect Dis, 2017, 3(8): 564-574. doi:10.1021/acsinfecdis.7b00046.
[15]	World Health Organization. WHO consolidated guidelines on tuberculosis: Module 5: Management of tuberculosis in children and adolescents. Geneva: World Health Organization, 2022.
[16]	Roelens M, Battista Migliori G, Rozanova L, et al. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis. Am J Respir Crit Care Med, 2021, 204(6): 713-722. doi:10.1164/rccm.202009-3527OC.
[17]	Anwar AI, Lu L, Plaisance CJ, et al. Fluoroquinolones: Neurological Complications and Side Effects in Clinical Practice. Cureus, 2024, 16(2): e54565. doi:10.7759/cureus.54565.
[18]	Shah I, Goyal A, Shetty NS. Adverse effects of aminoglycosides in children with drug resistant tuberculosis. Infect Dis (Lond), 2019, 51(3): 230-233. doi:10.1080/23744235.2018.1540884.
[19]	Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 399(10325): 629-655. doi:10.1016/S0140-6736(21)02724-0. pmid: 35065702
[20]	Kaufmann SHE, Dorhoi A, Hotchkiss RS, et al. Host-directed therapies for bacterial and viral infections. Nat Rev Drug Discov, 2018, 17(1): 35-56. doi:10.1038/nrd.2017.162. pmid: 28935918
[21]	Weber ANR, Bittner Z, Liu X, et al. Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity. Front Immunol, 2017, 8: 1454. doi:10.3389/fimmu.2017.01454.
[22]	Rip J, Van Der Ploeg EK, Hendriks RW, et al. The Role of Bruton’s Tyrosine Kinase in Immune Cell Signaling and Systemic Autoimmunity. Crit Rev Immunol, 2018, 38(1):17-62. doi:10.1615/CritRevImmunol.2018025184.
[23]	Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A, 2010, 107(29): 13075-13080. doi:10.1073/pnas.1004594107.
[24]	Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol, 2013, 31(1): 88-94. doi:10.1200/JCO.2012.42.7906. pmid: 23045577
[25]	Hu Y, Wen Z, Liu S, et al. Ibrutinib suppresses intracellular mycobacterium tuberculosis growth by inducing macrophage autophagy. J Infect, 2020, 80(6): e19-e26. doi:10.1016/j.jinf.2020.03.003.
[26]	Sparks IL, Derbyshire KM, Jacobs WR Jr, et al. Mycobacterium smegmatis: The Vanguard of Mycobacterial Research. J Bacteriol, 2023, 205(1): e0033722. doi:10.1128/jb.00337-22.
[27]	Lelovic N, Mitachi K, Yang J, et al. Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis. J Antibiot (Tokyo), 2020, 73(11): 780-789. doi:10.1038/s41429-020-0320-7.
[28]	T JAS, J R, Rajan A, et al. Features of the biochemistry of Mycobacterium smegmatis, as a possible model for Mycobacterium tuberculosis. J Infect Public Health, 2020, 13(9): 1255-1264. doi:10.1016/j.jiph.2020.06.023.